anti arrhythmia agents

Summary

Summary: Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Top Publications

  1. ncbi Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter
    Bramah N Singh
    Cardiology Division, Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    N Engl J Med 357:987-99. 2007
  2. ncbi A comparison of rate control and rhythm control in patients with atrial fibrillation
    D G Wyse
    AFFIRM Clinical Trial Center, Axio Research, 2601 4th Ave, Ste 200, Seattle, WA 98121, USA
    N Engl J Med 347:1825-33. 2002
  3. ncbi Rhythm control versus rate control for atrial fibrillation and heart failure
    Denis Roy
    Montreal Heart Institute and the Université de Montréal, Montreal, QC H1T 1C8, Canada
    N Engl J Med 358:2667-77. 2008
  4. ncbi Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
    W S Redfern
    Safety Assessment UK, AstraZeneca R and D Alderley Park, Macclesfield, Cheshire, UK
    Cardiovasc Res 58:32-45. 2003
  5. ncbi Quality of life in patients with atrial fibrillation: a systematic review
    Graham Thrall
    Cardiovascular Psychophysiology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom
    Am J Med 119:448.e1-19. 2006
  6. ncbi Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial
    S H Hohnloser
    JW Goethe University, Frankfurt, Germany
    Lancet 356:1789-94. 2000
  7. ncbi Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
    Scott D Corley
    Axio Research Corporation, Seattle, Wash, USA
    Circulation 109:1509-13. 2004
  8. ncbi Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Gust H Bardy
    Seattle Institute for Cardiac Research, Seattle, WA 98103, USA
    N Engl J Med 352:225-37. 2005
  9. ncbi Heart rate reduction during exercise-induced myocardial ischaemia and stunning
    Xavier Monnet
    Laboratoire de Pharmacologie, INSERM E 00 01, Faculte de Medecine Paris Sud, Paris, France
    Eur Heart J 25:579-86. 2004
  10. ncbi Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study
    Grzegorz Opolski
    Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
    Chest 126:476-86. 2004

Detail Information

Publications236 found, 100 shown here

  1. ncbi Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter
    Bramah N Singh
    Cardiology Division, Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    N Engl J Med 357:987-99. 2007
    ..Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects...
  2. ncbi A comparison of rate control and rhythm control in patients with atrial fibrillation
    D G Wyse
    AFFIRM Clinical Trial Center, Axio Research, 2601 4th Ave, Ste 200, Seattle, WA 98121, USA
    N Engl J Med 347:1825-33. 2002
    ..In both approaches, the use of anticoagulant drugs is recommended...
  3. ncbi Rhythm control versus rate control for atrial fibrillation and heart failure
    Denis Roy
    Montreal Heart Institute and the Université de Montréal, Montreal, QC H1T 1C8, Canada
    N Engl J Med 358:2667-77. 2008
    ..However, the benefits and risks of this approach have not been adequately studied...
  4. ncbi Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
    W S Redfern
    Safety Assessment UK, AstraZeneca R and D Alderley Park, Macclesfield, Cheshire, UK
    Cardiovasc Res 58:32-45. 2003
    ..To attempt to determine the relative value of preclinical cardiac electrophysiology data (in vitro and in vivo) for predicting risk of torsade de pointes (TdP) in clinical use...
  5. ncbi Quality of life in patients with atrial fibrillation: a systematic review
    Graham Thrall
    Cardiovascular Psychophysiology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom
    Am J Med 119:448.e1-19. 2006
    ..The data, although frequently compromised by various methodologic weaknesses, suggest that patients with AF have impaired QoL, and that QoL can be significantly improved through rate or rhythm-control strategies...
  6. ncbi Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial
    S H Hohnloser
    JW Goethe University, Frankfurt, Germany
    Lancet 356:1789-94. 2000
    ..Restoration and maintenance of sinus rhythm is believed by many physicians to be superior to rate control only. However, there are no prospective data that compare both therapeutic strategies...
  7. ncbi Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
    Scott D Corley
    Axio Research Corporation, Seattle, Wash, USA
    Circulation 109:1509-13. 2004
    ..This article reports an "on-treatment" analysis of the relationship of survival to cardiac rhythm and treatment as they changed over time...
  8. ncbi Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Gust H Bardy
    Seattle Institute for Cardiac Research, Seattle, WA 98103, USA
    N Engl J Med 352:225-37. 2005
    ..Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients...
  9. ncbi Heart rate reduction during exercise-induced myocardial ischaemia and stunning
    Xavier Monnet
    Laboratoire de Pharmacologie, INSERM E 00 01, Faculte de Medecine Paris Sud, Paris, France
    Eur Heart J 25:579-86. 2004
    ..The effects of selective heart rate reduction by ivabradine (If inhibitor) were compared to those of atenolol on exercise-induced ischaemia and stunning...
  10. ncbi Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study
    Grzegorz Opolski
    Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
    Chest 126:476-86. 2004
    ..The relative risks and benefits of strategies of rate control vs rhythm control in patients with atrial fibrillation (AF) remain to be fully explored...
  11. ncbi Contributions of heart rate and contractility to myocardial oxygen balance during exercise
    Patrice Colin
    Laboratoire de Pharmacologie, INSERM E 00 01, Faculte de Medecine Paris Sud, 94270 Le Kremlin Bicetre, France
    Am J Physiol Heart Circ Physiol 284:H676-82. 2003
    ..Thus HR reduction and negative inotropy equally contribute to the reduction in MVo(2) during exercise in the normal heart. The negative inotropy limits the increase in DT afforded by HR reduction...
  12. ncbi Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial
    Oussama M Wazni
    Department of Cardiovascular Medicine, Center for Atrial Fibrillation, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 293:2634-40. 2005
    ..Pulmonary vein isolation (PVI) with radiofrequency ablation may cure AF, obviating the need for antiarrhythmic drugs and anticoagulation...
  13. ncbi ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice
    Valentin Fuster
    Circulation 114:e257-354. 2006
  14. ncbi Ventricular fibrillation: how do we stop the waves from breaking?
    J N Weiss
    Cardiovascular Research Laboratory and the Departments of Medicine Cardiology, Physiology and Physiological Science, UCLA School of Medicine and Cedars Sinai Medical Center, Los Angeles, CA 90095 1760, USA
    Circ Res 87:1103-7. 2000
    ..Developing therapies that favorably alter electrical restitution properties have promise as a new paradigm for preventing fibrillation...
  15. ncbi Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial
    Denis Roy
    Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada
    Circulation 117:1518-25. 2008
    ..The present study assessed the efficacy and safety of vernakalant hydrochloride (RSD1235), a novel compound, for the conversion of atrial fibrillation (AF)...
  16. ncbi Heart rate variability in myocardial infarction and heart failure
    Nipon Chattipakorn
    Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    Int J Cardiol 120:289-96. 2007
    ..In this article, the current role of HRV in the prediction of cardiovascular mortality in myocardial infarction and heart failure patients has been reviewed...
  17. ncbi Adverse effects of low dose amiodarone: a meta-analysis
    V R Vorperian
    Department of Medicine, University of Wisconsin School of Medicine, Madison, USA
    J Am Coll Cardiol 30:791-8. 1997
    ..We sought to assess the odds of experiencing adverse effects with low dose amiodarone therapy compared with placebo...
  18. ncbi Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation
    Robby Nieuwlaat
    Department of Cardiology, University Hospital Maastricht, P Debyelaan 25, PO Box 5800, Maastricht 6202AZ, Maastricht, The Netherlands
    Eur Heart J 26:2422-34. 2005
    ..To describe atrial fibrillation (AF) management in member countries of the European Society of Cardiology (ESC) and to verify cardiology practices against guidelines...
  19. ncbi Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643)
    Rie Schultz Hansen
    Neurosearch A S, Pederstrupvej 93, 2750 Ballerup, Denmark
    Mol Pharmacol 69:266-77. 2006
    ..In conclusion, HERG channel activation by small molecules such as NS1643 increases the repolarization reserve and presents an interesting new antiarrhythmic approach...
  20. ncbi Atrial fibrillation after cardiac surgery
    W H Maisel
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Ann Intern Med 135:1061-73. 2001
    ..To review the epidemiology, mechanisms, complications, predictors, prevention, and treatment of atrial fibrillation following cardiac surgery...
  21. ncbi Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis
    Simon de Denus
    Pharmacy Department, Montreal Heart Institute Faculty of Pharmacy, University of Montreal, Montreal, Quebec
    Arch Intern Med 165:258-62. 2005
    ....
  22. ncbi Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion
    Chung Wah Siu
    Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Am J Cardiol 92:1343-5. 2003
    ..The result of this retrospective study demonstrates that the use of statins in patients with lone AF was associated with a significant decrease in the risk of arrhythmia recurrence after successful cardioversion...
  23. ncbi C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation
    J Dernellis
    Department of Cardiology, Vostanion Hospital, Mytilini, Greece
    Acta Cardiol 56:375-80. 2001
    ..CONCLUSION: These results suggest that CRP has a strong association with PAF and support the hypothesis that CRP is a potent determinant of successful cardioversion of PAF in sinus rhythm...
  24. ncbi Molecular determinants of dofetilide block of HERG K+ channels
    E Ficker
    Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44109 1998, USA
    Circ Res 82:386-95. 1998
    ..Thus, the serine in position HERG 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding...
  25. ncbi ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Comm
    Valentin Fuster
    J Am Coll Cardiol 48:854-906. 2006
  26. ncbi Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode
    Francisco G Cosio
    Hospital Universitario de Getafe, Carretera de Toledo, km 12, 5 Getafe, 28905 Madrid, Spain
    Europace 10:21-7. 2008
    ....
  27. ncbi Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses
    Hugh Calkins
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Circ Arrhythm Electrophysiol 2:349-61. 2009
    ....
  28. ncbi Hepatic cirrhosis caused by low-dose oral amiodarone therapy
    Srinivas R Puli
    Department of Medicine, St John s Mercy Medical Center, St Louis, Missouri 63141, USA
    Am J Med Sci 330:257-61. 2005
    ..This is the first reported case of amiodarone-induced hepatic cirrhosis associated with chronic treatment with 200 mg orally once per day for less than 2 years...
  29. pmc Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells
    A O Grant
    Departments of Medicine and Pediatrics, Duke University, Durham, NC 27706, USA
    Biophys J 79:3019-35. 2000
    ..The qualitative differences in use-dependent block appear to be the result of differences in drug dissociation rate. The inactivation gate may play a trapping role during exposure to some sodium channel blocking drugs...
  30. pmc Preventing ventricular fibrillation by flattening cardiac restitution
    A Garfinkel
    Department of Medicine Cardiology, Cardiovascular Research Laboratory, University of California School of Medicine, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 97:6061-6. 2000
    ..It even converts existing fibrillation, either to a periodic state (ventricular tachycardia, which is much more easily controlled) or to quiescent healthy tissue...
  31. pmc Drug induced QT prolongation and torsades de pointes
    Yee Guan Yap
    Department of Cardiological Sciences, St George s Hospital Medical School, London, UK
    Heart 89:1363-72. 2003
  32. ncbi Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials
    Carmelo Lafuente-Lafuente
    Service de Medecine Interne A, Hopital Lariboisiere, Paris, France
    Arch Intern Med 166:719-28. 2006
    ..We performed a systematic review to determine the effect of long-term treatment with those drugs on death, embolisms, adverse effects, and atrial fibrillation recurrence...
  33. ncbi Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery
    Hans Geertman
    Department of Cardiology, Cardiothoracic Anesthesia and Cardiac Surgery, Isala Clinics, Weezenlanden Hospital, Zwolle, The Netherlands
    J Cardiothorac Vasc Anesth 18:309-12. 2004
    ..Several etiologic factors are mentioned. Prophylactic intervention with sotalol is reported to reduce the incidence of POAT. The authors studied the effect of magnesium chloride (MgCl2) in addition to sotalol in the prevention of POAT...
  34. ncbi Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group
    P R Kowey
    Lankenau Hospital and Medical Research Center, Wynnewood, PA 19096, USA
    Circulation 92:3255-63. 1995
    ..Therefore, an intravenous form of therapy is advantageous. This study was designed to compare the safety and efficacy of a high and a low dose of intravenous amiodarone with bretylium, the only approved class III antiarrhythmic agent...
  35. ncbi Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels
    L Wang
    Division of Cardiovascular Medicine, University of California, Davis 95616, USA
    Am J Physiol Heart Circ Physiol 280:H2321-8. 2001
    ..These data suggest that the lowering of mitochondrial calcium overload is a mechanism of cardioprotection in PC...
  36. ncbi Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial
    S Giri
    Division of Cardiology, Brigham and Women's Hospital, Harvard University School of Medicine, Boston, MA, USA
    Lancet 357:830-6. 2001
    ..0%) were similar. INTERPRETATION: Oral amiodarone prophylaxis in combination with beta-blockers prevents atrial fibrillation and symptomatic fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia...
  37. ncbi Effects of amiodarone on wave front dynamics during ventricular fibrillation in isolated swine right ventricle
    Chikaya Omichi
    Division of Cardiology, Department of Medicine, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90048 1865, USA
    Am J Physiol Heart Circ Physiol 282:H1063-70. 2002
    ..We conclude that amiodarone reduced spontaneous wave breaks. It might terminate VF or convert VF to VT. These effects were associated with the flattening of APD restitution slope and increased core size of reentrant wave fronts...
  38. ncbi Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione
    Roberto Marchioli
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Circulation 105:1897-903. 2002
    ..Our purpose was to assess the time course of the benefit of n-3 polyunsaturated fatty acids (PUFAs) on mortality documented by the GISSI-Prevenzione trial in patients surviving a recent (<3 months) myocardial infarction...
  39. ncbi Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
    Joachim R Ehrlich
    Division of Clinical Electrophysiology, J W Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Eur Heart J 27:512-8. 2006
    ..This exciting field of investigation may lead to significant improvements in therapeutic options for AF patients...
  40. ncbi Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 54:1089-95. 2009
    ..We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF)...
  41. ncbi Dronedarone
    Chinmay Patel
    Main Line Health Heart Center and Lankenau Hospital, Wynnewood, PA 19096, USA
    Circulation 120:636-44. 2009
    ..This article will review evidence of safety and effectiveness of dronedarone in patients with atrial fibrillation...
  42. ncbi Prophylaxis of supraventricular and ventricular arrhythmias after coronary artery bypass grafting with low-dose sotalol
    P Evrard
    Division of Intensive Care Medicine, Mont Godinne University Hospital, Universite Catholique de Louvain, Yvoir, Belgium
    Ann Thorac Surg 70:151-6. 2000
    ..Supraventricular tachyarrhythmia (SVT) commonly occurs shortly after coronary artery bypass grafting (CABG), but ventricular arrhythmias are less documented...
  43. ncbi Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study
    Vincent E Hagens
    Department of Cardiology, University Hospital, Groningen, Netherlands
    J Am Coll Cardiol 43:241-7. 2004
    ..We studied the influence of rate control or rhythm control in patients with persistent atrial fibrillation (AF) on quality of life (QoL)...
  44. ncbi Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm
    F J Martinez-Marcos
    Servicio de Cuidados Críticos Urgencias, Hospital Juan Ramon Jimenez, Huelva, Spain
    Am J Cardiol 86:950-3. 2000
    ..Propafenone and amiodarone have similar conversion rates, although propafenone was faster in achieving the conversion to sinus rhythm...
  45. ncbi Controversies in atrial fibrillation
    Stanley Nattel
    Department of Medicine and Research Centre, Montreal Heart Institute, University of Montreal, Montreal, Quebec H1T 1C8, Canada
    Lancet 367:262-72. 2006
    ..The background of every controversy is reviewed and our opinions expressed. Here, we hope to inform physicians about the most important controversies in this specialty and stimulate investigators to address unresolved issues...
  46. ncbi Functional consequences of a domain 1/S6 segment sodium channel mutation associated with painful congenital myotonia
    D W Wang
    Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    FEBS Lett 448:231-4. 1999
    ..Our findings demonstrate the unique pattern of sodium channel dysfunction associated with a D1/S6 myotonia-producing sodium channel mutation, and provide a mechanism for the beneficial effects of flecainide in this setting...
  47. ncbi Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts
    Richard Balasubramaniam
    Physiological Laboratory, University of Cambridge, Downing Street, Cambridge, CB2 3EG, United Kingdom
    Pflugers Arch 449:150-8. 2004
    ..Taken together, the findings may have implications for the use of L-type Ca(2+) channel blockade in conditions associated with beta-adrenergically driven ventricular arrhythmias such as cardiac failure and LQTS...
  48. pmc State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide
    Ging Kuo Wang
    Department of Anesthesia, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Gen Physiol 122:365-74. 2003
    ..We conclude that flecainide directly blocks persistent late Na+ currents with a high affinity. The fast-inactivation gate, probably via its S6 docking site, may further stabilize the flecainide-receptor complex in wild-type Na+ channels...
  49. ncbi National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation
    Margaret C Fang
    Massachusetts General Hospital, Boston, USA
    Arch Intern Med 164:55-60. 2004
    ..Atrial fibrillation is the most common cardiac arrhythmia associated with significant medical complications. We examined trends in the medical therapy of atrial fibrillation in the United States from 1991 through 2000...
  50. ncbi Anti-inflammatory therapies in atrial fibrillation
    Tong Liu
    Int J Cardiol 104:359-60. 2005
  51. ncbi Effects of procainamide on electrical activity in thoracic veins and atria in canine model of sustained atrial fibrillation
    Chung Chuan Chou
    Division of Cardiology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Am J Physiol Heart Circ Physiol 286:H1936-45. 2004
    ..Second, FDs in the PV are more resistant to procainamide's action than FDs in the atria. Third, inherent PV ERP is important in determining the antifibrillatory efficacy of procainamide...
  52. ncbi A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation
    Isabelle C Van Gelder
    Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands
    N Engl J Med 347:1834-40. 2002
    ..We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation...
  53. ncbi Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial
    Paulus Kirchhof
    Department of Cardiology and Angiology, Hospital of the University of Münster, Germany
    Am Heart J 150:899. 2005
    ....
  54. ncbi Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach
    Paolo Alboni
    Division of Cardiology, Ospedale Civile, Cento, Italy
    N Engl J Med 351:2384-91. 2004
    ..We evaluated the feasibility and the safety of self-administered oral loading of flecainide and propafenone in terminating atrial fibrillation of recent onset outside the hospital...
  55. ncbi The novel antiarrhythmic drug dronedarone: comparison with amiodarone
    Sven Kathofer
    Department of Cardiology, Medical University Hospital Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Cardiovasc Drug Rev 23:217-30. 2005
    ..However, further experimental studies and long-term clinical trials are required to provide additional evidence of efficacy and safety of dronedarone...
  56. ncbi Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies
    Stanley Nattel
    Department of Medicine and Research Center, University of Montreal, Montreal, Canada
    J Cardiovasc Electrophysiol 14:S133-9. 2003
    ..A better understanding of the ways in which Na+ channel blockers affect AF will be useful, not only for new antiarrhythmic drug development but also for gaining insight into the mechanisms of the arrhythmia...
  57. ncbi Efficacy of quinidine in high-risk patients with Brugada syndrome
    Bernard Belhassen
    Department of Cardiology, Tel Aviv Sourasky Medical Center, and Tel Aviv University, Sackler School of Medicine, Weizman St 6, Tel Aviv 64239 Israel
    Circulation 110:1731-7. 2004
    ..Quinidine depresses I(to) current, which may play an important role in the arrhythmogenesis of this disease...
  58. pmc Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action
    Sandra Fredj
    Department of Pharmacology, Columbia University Medical Center, New York, NY 10032, USA
    Br J Pharmacol 148:16-24. 2006
    ....
  59. ncbi Cost-effectiveness of rhythm versus rate control in atrial fibrillation
    Deborah A Marshall
    Center for Evaluation of Medicine, McMaster University and St Joseph s Hospital, Hamilton, Ontario, Canada
    Ann Intern Med 141:653-61. 2004
    ..Consequently, economic factors often play a role in guiding treatment selection...
  60. ncbi Cardioprotective effects and underlying mechanisms of oxymatrine against Ischemic myocardial injuries of rats
    Sun Hong-Li
    Department of Pharmacology, Harbin Medical University, Bio Pharmaceutical Engineering Key Laboratory of Heilongjiang Province Incubator of State Key Laboratory, Harbin 150081, P R China
    Phytother Res 22:985-9. 2008
    ....
  61. ncbi Increased mortality after dronedarone therapy for severe heart failure
    Lars Køber
    Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark
    N Engl J Med 358:2678-87. 2008
    ..Therefore, it may be of value in the treatment of patients with heart failure...
  62. pmc Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation
    Colleen E Clancy
    Dept of Physiology and Biophysics, Insitute for Computational Biomedicine, Weill Medical College of Cornell Univeristy, 1300 York Ave, LC 501E, New York, NY 10021, USA
    Am J Physiol Heart Circ Physiol 292:H66-75. 2007
    ..The simulations also suggest that inactivation state block by lidocaine is less effective in restoring normal repolarization and adversely suppresses peak Na(+) current...
  63. ncbi Mitochondria are targets for geranylgeranylacetone-induced cardioprotection against ischemia-reperfusion in the rat heart
    Tetsuji Shinohara
    Department of Internal Medicine 1, Faculty of Medicine, Oita University, 1 1 Idaigaoka, Hasama, Oita 879 5593, Japan
    Am J Physiol Heart Circ Physiol 293:H1892-9. 2007
    ..These processes may involve opening of the mitoK(ATP) channel...
  64. pmc Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome
    Ian N Sabir
    Physiological Laboratory, University of Cambridge, Downing Street, Cambridge CB2 3EG, UK
    Pflugers Arch 455:637-51. 2008
    ..We thus associate changes in the slopes of restitution curves with arrhythmogenicity in models of LQT3 and BrS...
  65. pmc Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation
    Subeena Sood
    Department of Molecular Physiology and Biophysics, Houston, Texas 77030, USA
    Heart Rhythm 5:1047-54. 2008
    ..Studies in patients with AF revealed that impaired diastolic closure of sarcoplasmic reticulum (SR) Ca(2+)-release channels (ryanodine receptors, RyR2) is associated with reduced levels of the RyR2-inhibitory subunit FKBP12.6...
  66. ncbi Benzofuran derivatives and the thyroid
    T S Han
    Department of Endocrinology, Royal Free and University College Medical School, Royal Free Hospital, Hampstead, London NW3 2QG, UK
    Clin Endocrinol (Oxf) 70:2-13. 2009
    ..It may have a future role as an alternative agent in patients being considered for amiodarone therapy especially those at high risk of developing thyroid dysfunction but not in severe heart failure...
  67. ncbi The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy
    Savina Nodari
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, c o Spedali Civili, P zza Spedali Civili, 25100, Brescia, Italy
    Cardiovasc Drugs Ther 23:5-15. 2009
    ..Their effects in patients with heart failure caused by idiopathic dilated cardiomyopathy (IDC) are unknown...
  68. ncbi Effect of dronedarone on cardiovascular events in atrial fibrillation
    Stefan H Hohnloser
    Department of Cardiology, J W Goethe University, Frankfurt, Germany
    N Engl J Med 360:668-78. 2009
    ..Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation...
  69. pmc Pharmacological changes in cellular Ca2+ homeostasis parallel initiation of atrial arrhythmogenesis in murine Langendorff-perfused hearts
    Yanmin Zhang
    Physiological Laboratory, University of Cambridge, Cambridge, UK
    Clin Exp Pharmacol Physiol 36:969-80. 2009
    ....
  70. ncbi Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model
    Keiichi Ashikaga
    The Second Department of Internal Medicine, Hirosaki University School of Medicine, Zaifu cho 5, Hirosaki, 036 8562, Japan
    Eur J Pharmacol 536:148-53. 2006
    ..Amiodarone reversed both of them, which may be related to its high efficacy in preventing recurrence of persistent atrial fibrillation...
  71. ncbi New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation
    Paulus Kirchhof
    Department of Cardiology and Angiology, Hospital of the University of Münster, Munster, Germany
    Heart Rhythm 4:790-3. 2007
    ....
  72. ncbi Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study
    Carlo Pappone
    Clinical Cardiac Electrophysiology and Pacing Unit, Department of Cardiology, San Raffaele University Hospital, Milan, Italy
    J Am Coll Cardiol 42:185-97. 2003
    ....
  73. ncbi Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study
    Gerian C Gronefeld
    Department of Medicine, Division of Cardiology, J W Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Eur Heart J 24:1430-6. 2003
    ..This prospective study evaluated QoL in patients with symptomatic persistent AF randomized to therapy aiming at rate versus rhythm control...
  74. ncbi Dronedarone for prevention of atrial fibrillation: a dose-ranging study
    Paul Touboul
    Division of Cardiology, Hopital Cardiologique, Lyon, France
    Eur Heart J 24:1481-7. 2003
    ..This study was designed to determine the most appropriate dose of dronedarone for prevention of atrial fibrillation (AF) after cardioversion...
  75. ncbi Dronedarone: a new antiarrhythmic agent
    Karolina M Zareba
    University of Rochester School of Medicine, Rochester, New York 14642, USA
    Drugs Today (Barc) 42:75-86. 2006
    ..Other clinical applications of this novel antiarrhythmic drug need to be determined in future clinical trials...
  76. ncbi Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study
    Grzegorz Opolski
    Chair and Department of Internal Medicine and Cardiology, Medical Academy, Warsaw, Poland
    Kardiol Pol 59:1-16; discussion 15-16. 2003
    ..Which of these two strategies is superior, has not yet been definitively established...
  77. ncbi Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial
    Stuart J Connolly
    FRCPC, Division of Cardiology, Hamilton Health Sciences, General Site, 502 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada
    Circulation 120:1174-80. 2009
    ....
  78. ncbi Amiodarone--avoid the danger of torsade de pointes
    Paul Foley
    University of Birmingham, Good Hope Hospital, Rectory Road, Sutton Coldfield B75 7RR, United Kingdom
    Resuscitation 76:137-41. 2008
    ..These cases highlight the need for careful attention to the indications, cautions and contra-indications of amiodarone as well as the need for vigilance following initiation of anti-arrhythmic therapy...
  79. ncbi Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study
    Jorg Carlsson
    Department of Internal Medicine II, Klinikum Lippe Detmold, Röntgenstrasse 18, D 32760 Detmold, Germany
    J Am Coll Cardiol 41:1690-6. 2003
    ....
  80. ncbi Modulation of the hyperpolarization-activated inward current (If) by antiarrhythmic agents in isolated human atrial myocytes
    U C Hoppe
    Department of Medicine III, University of Cologne, Germany
    Naunyn Schmiedebergs Arch Pharmacol 358:635-40. 1998
    ..However, it has yet to be defined whether these agents suppress atrial tachycardias via an inhibition of If in vivo...
  81. ncbi ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Commi
    Valentin Fuster
    American College of Cardiology, Bethesda, MD 20814, USA
    Eur Heart J 27:1979-2030. 2006
  82. ncbi Dronedarone: an emerging agent with rhythm- and rate-controlling effects
    Florian T Wegener
    Division of Electrophysiology, Department of Cardiology, J W Goethe University, Frankfurt, Germany
    J Cardiovasc Electrophysiol 17:S17-20. 2006
    ....
  83. pmc Brugada syndrome
    Carlo Napolitano
    Molecular Cardiology Laboratories, IRCCS, Fondazione Salvatore Maugeri, Via Ferrata 8, 27100 Pavia, Italy
    Orphanet J Rare Dis 1:35. 2006
    ..Quinidine may be regarded as an adjunctive therapy for patients at higher risk and may reduce the number of cases of ICD shock in patients with multiple recurrences...
  84. ncbi Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins
    Li Wei Lo
    National Yang Ming University, School of Medicine, Division of Cardiology and Cardiovascular Research Center, Taipei Veterans General Hospital, Taiwan
    Eur J Pharmacol 571:197-208. 2007
    ..In conclusion, calmodulin kinase II inhibition may prevent adrenergic induced pulmonary vein arrhythmogenesis...
  85. ncbi Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial
    Stuart J Connolly
    Department of Medicine, McMaster University, Hamilton, Ontario
    JAMA 295:165-71. 2006
    ..Implantable cardioverter defibrillator (ICD) therapy is effective but is associated with high-voltage shocks that are painful...
  86. ncbi Drug therapy for atrial fibrillation
    Simone Musco
    Division of Cardiovascular Diseases, Main Line Heart Center, 556 Medical Office, Building East, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
    Med Clin North Am 92:121-41, xi. 2008
    ..New antiarrhythmic drugs are being tested in clinical trials. Drugs that target remodeling and inflammation are being tested for their use as prevention of AF or as adjunctive therapy...
  87. pmc Greater antiarrhythmic activity of acute 17beta-estradiol in female than male anaesthetized rats: correlation with Ca2+ channel blockade
    K L Philp
    Department of Pharmacology and Therapeutics, UK
    Br J Pharmacol 149:233-42. 2006
    ..We therefore investigated the effects of the main female sex hormone, 17beta-estradiol, on ischaemia-induced cardiac arrhythmias and on the L-type Ca2+ current (ICaL)...
  88. ncbi Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion
    Mehmet Ozaydin
    Department of Cardiology, Suleyman Demirel University Medical School, Isparta, Turkey
    Am J Cardiol 97:1490-3. 2006
    ..82 +/- 1.46 vs 2.56 +/- 1.3 mg/dl, p = 0.02), no significant change occurred in group II (2.87 +/- 0.8 vs 2.84 +/- 0.8 mg/dl, p = 0.09). In conclusion, atorvastatin decreased the recurrence rate of AF after EC...
  89. pmc Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in DeltaKPQ Scn5a murine hearts modelling human long QT 3 syndrome
    G Thomas
    Section of Cardiovascular Biology, Department of Biochemistry, University of Cambridge, Cambridge, UK
    Acta Physiol (Oxf) 192:505-17. 2008
    ..To perform an empirical, pharmacological, separation of early afterdepolarizations (EADs) and transmural gradients of repolarization in arrhythmogenesis in a genetically modified mouse heart modelling human long QT syndrome (LQT) 3...
  90. pmc Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome
    Christian Wolpert
    1st Department of Medicine Cardiology, University Hospital of Mannheim, Faculty of Clinical Medicine of the University of Heidelberg, Germany
    Heart Rhythm 2:254-60. 2005
    ..The purpose of this study was to compare the effect of intravenous flecainide and ajmaline with respect to their ability to induce or accentuate the typical ECG pattern of Brugada syndrome...
  91. pmc Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the Brugada syndrome
    Kate S Stokoe
    Physiological Laboratory, University of Cambridge, Downing Street, Cambridge CB2 3EG, UK
    J Physiol 581:255-75. 2007
    ....
  92. ncbi A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation
    Michael John Davey
    Department of Emergency Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
    Ann Emerg Med 45:347-53. 2005
    ..We examine the safety and efficacy of magnesium sulfate infusion, in addition to usual care, for acute rate reduction in patients with atrial fibrillation and a rapid ventricular response rate...
  93. ncbi Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment?
    D R Tomlinson
    Department of Cardiac Rhythm Management, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK
    Emerg Med J 25:15-8. 2008
    ..To examine the efficacy of bolus dose intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained monomorphic ventricular tachycardia (VT)...
  94. pmc A quantitative analysis of the effect of cycle length on arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts
    Ian N Sabir
    Physiological Laboratory, University of Cambridge, Downing Street, Cambridge, CB2 3EG, UK
    Pflugers Arch 454:925-36. 2007
    ....
  95. ncbi Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation
    Paulus Kirchhof
    Medizinische Klinik und Poliklinik C Kardiologie und Angiologie, Universitatsklinikum Munster, Munster, Germany
    Basic Res Cardiol 100:112-21. 2005
    ..We studied whether two antiarrhythmic drugs (sotalol, flecainide) prolong APD or induce PRR in the fibrillating human atrium...
  96. ncbi Torsades de pointes following cardioversion: case history and literature review
    Doug Spearritt
    ICU, St Vincents Hospital, Toowoomba, QLD
    Aust Crit Care 16:144-9. 2003
    ..Typical progressive rhythm strip, electrocardiograph (ECG), and QT & corrected QT interval (QTc) interval changes occurring with the arrhythmia are presented...
  97. ncbi Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome
    B Belhassen
    Department of Cardiology, Tel Aviv Sourasky Medical Center, Israel
    J Cardiovasc Electrophysiol 10:1301-12. 1999
    ..We sought to study the long-term value of electrophysiologic (EP)-guided therapy with Class IA antiarrhythmic drugs in patients with idiopathic VF with or without the Brugada syndrome...
  98. ncbi Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure
    Bruce S Stambler
    Department of Medicine Cardiology, West Roxbury Veterans Affairs Medical Center, Harvard Medical School, West Roxbury, Massachusetts, USA
    J Cardiovasc Electrophysiol 14:499-507. 2003
    ..Atrial arrhythmias often complicate congestive heart failure (CHF). We characterized inducible atrial tachyarrhythmias and electrophysiologic alterations in dogs with CHF and atrial enlargement produced by rapid ventricular pacing...
  99. ncbi Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol
    Luiz R Leite
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Cardiovasc Electrophysiol 14:567-73. 2003
    ..This study assessed the role of electrophysiologic testing to identify therapeutic strategies for the treatment of patients with sustained ventricular tachycardia (VT) and chronic chagasic cardiomyopathy treated with amiodarone or sotalol...
  100. ncbi Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation--a case report
    Louis Voigt
    New York Methodist Hospital, Brooklyn, NY 11215, USA
    Angiology 54:229-31. 2003
    ..In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia...
  101. pmc Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation
    G Nichol
    Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada
    Heart 87:535-43. 2002
    ..To conduct a meta-analysis of randomised controlled trials to estimate the effectiveness of antiarrhythmic drugs at promoting sinus rhythm in patients with atrial fibrillation...

Research Grants62

  1. Structural and molecular basis of drug-induced IKACh reduction
    SAMI FOUAD NOUJAIM; Fiscal Year: 2013
    ..abstract_text> ..
  2. Structural and molecular basis of drug-induced IKACh reduction
    SAMI FOUAD NOUJAIM; Fiscal Year: 2012
    ..abstract_text> ..
  3. Targeted cell therapy for the treatment of ventricular tachycardia
    KENNETH LAURITA; Fiscal Year: 2010
    ..Consequently, SCD remains a major unresolved public health problem. This proposal puts forth a novel method using targeted cellular therapy to restore normal function and, thus, cure many patients at risk for SCD. 1 ..
  4. NOVEL CATHETER FOR TREATMENT OF VENTRICULAR TACHYCARDIA
    Michael G Curley; Fiscal Year: 2010
    ..At minimum the shocks these patients receive severely reduce their quality of life. At worst the patient remains susceptible to sudden cardiac death. An effective and inexpensive method of treating these patients VTs is urgently needed. ..
  5. Positional Cloning and Candidate Gene Approach to Familial Atrial Fibrilation
    Dawood Darbar; Fiscal Year: 2012
    ..The improved understanding of the diverse mechanisms leading to AF represents a first step in the development of subtype-specific therapeutic treatments for this common and morbid condition. ..
  6. ANCILLARY STUDY OF SUBSTRATE AND INTERVENTION MECHANISMS FOR MALIGNANT ARRHYTHMIA
    Saman Nazarian; Fiscal Year: 2013
    ..The findings of this study will have wide applicability to optimization of management strategies for patients with post-infarct VT. ..
  7. SURGICAL TREATMENT OF CARDIAC ARRHYTHMIAS
    Ralph J Damiano; Fiscal Year: 2013
    ..The present proposal is design to improve and simplify this surgical treatment, maintain the high cure rate, and minimize the effects on heart function, thus making it available to a wider patient population. ..
  8. cPKC Regulation of Cardiac Potassium Channels
    Coeli M B Lopes; Fiscal Year: 2013
    ....
  9. Treatment of Sleep Disordered Breathing in Atrial Fibrillation
    SEAN MICHAEL CAPLES; Fiscal Year: 2010
    ..Our proposal will, for the first time, determine whether treatment of sleep apnea helps prevent development of AF. ..
  10. Structural Basis for Antiarrhythmic Drug Action
    Ning Zheng; Fiscal Year: 2013
    ..This information will provide the structural basis for discovery and development of safer and more effective AADs. ..
  11. ROLE OF PROLONGED REPOLARIZATION IN CARDIAC ARRHYTHMIAS
    Dan Roden; Fiscal Year: 1992
    ....
  12. IN VIVO ACTIONS OF ANTIARRHYTHMIC DRUGS
    Dan Roden; Fiscal Year: 1990
    ..This research will increase our understanding of the basic mechanisms of actions of antiarrhythmic drugs in the whole heart and has the potential to immediately improve care of patients with life-threatening arrhythmias...
  13. QT Interval Remodeling in Atrial Fibrillation
    Dawood Darbar; Fiscal Year: 2012
    ..abstract_text> ..
  14. CLOSED-LOOP IMPLANTABLE ANTIARRHYTHMIC DRUG INFUSION
    Robert Arzbaecher; Fiscal Year: 1993
    ....
  15. Substrate Mapping & Ablation of Ventricular Tachycardia
    Vivek Reddy; Fiscal Year: 2006
    ..abstract_text> ..
  16. VERY LOW ENERGY CARDIOVERSION FOR ATRIAL FIBRILLATION
    Patrick Wolf; Fiscal Year: 2003
    ..These advances will increase our understanding of the progression of AF and allow a successful therapy for this debilitating disease to be more broadly applied. ..
  17. CARDIAC DISEASE IN COOLEYS ANEMIA--MOLE AND CLIN STUDIES
    Gary Brittenham; Fiscal Year: 2002
    ....
  18. INTERACTION OF ISCHEMIA, DRUGS, AND RATE ON CONDUCTION
    Wayne Cascio; Fiscal Year: 1991
    ....
  19. FORMS AND RESPONSES OF VENTRICULAR ARRHYTHMIAS
    Robert Myerburg; Fiscal Year: 1990
    ....
  20. THE MOLECULAR BASIS OF ELECTRICAL EXCITABILITY
    William Catterall; Fiscal Year: 1980
    ..Impairment of such regulatory mechanisms may play an important role in the etiology of chronic arrhythmias and other aspects of heart disease...
  21. MOLECULAR DETERMINANTS OF POTASSIUM CHANNEL DRUG BLOCK
    Dirk Snyders; Fiscal Year: 2003
    ....
  22. Regions of Na channel involved in permeation and gating
    Nipavan Chiamvimonvat; Fiscal Year: 2002
    ..Definition of the regions determining ion transport, selectivity and gating hold promises for new and more mechanistic approaches for our diagnosis and therapy of cardiovascular ion channel diseases. ..
  23. STEROSPECIFIC ANALYSIS OF NEW ANTIARRHYTHMIC AGENTS
    Joseph Gal; Fiscal Year: 1990
    ..g., the separate enantiomers. Furthermore, the methods developed may have general applicability to many other chiral drugs...
  24. DRUG EFFECTS ON IMPULSE INITIATION IN THE HEART
    KENNETH DANGMAN; Fiscal Year: 1991
    ....
  25. Molecular Mechanisms of Cardiac Arrhythmias
    Qing Wang; Fiscal Year: 2005
    ..These studies may provide a new framework for the rational design of therapeutic agents. ..
  26. Access Paths for Sodium-Channel Blocking Antiarrhythmics
    Peter Lee; Fiscal Year: 2005
    ..The University of Chicago, an institution of international prominence in medical and basic science provides a rigorous academic environment with extensive resources for fostering a successful academic career. ..
  27. AUTONOMIC CARDIAC ACTIVITY DURING ISCHEMIA
    GILBERT HAGEMAN; Fiscal Year: 1992
    ....
  28. ANTIARRHYTHMIC DRUGS--SINGLE CHANNEL BLOCKING MECHANISMS
    Paul Bennett; Fiscal Year: 1993
    ....
  29. MOLECULAR INTERACTIONS BETWEEN LIDOCAINE AND NA CHANNELS
    NICHOLAS KAMBOURIS; Fiscal Year: 1999
    ..These goals will serve as a platform upon which to develop a career as an independent investigator in ion-channel electrophysiology and pharmacology. ..
  30. LIPOSOME MYOCARDIAL UPTAKE IN INFARCT AND ISCHEMIA
    VICENTE CARIDE; Fiscal Year: 1980
    ..Therapeutic efficiency in this instance will be monitored by assessment of regional refractory periods. ..
  31. OPTICAL MONITORING OF REENTRY AND ANTIARRHYTHMIC ACTION
    BRUCE HILL; Fiscal Year: 1990
    ....
  32. PHARMACOGENOMICS OF ARRHYTHMIA THERAPY
    Dan Roden; Fiscal Year: 2009
    ..Participation in the Network will enable the long-term vision of exploiting human genomic information for more rationale drug development and ..
  33. Data collection & integration in cardiac risk assessment
    GREGERY BUZZARD; Fiscal Year: 2005
    ..abstract_text> ..
  34. REGULATION OF INWARD RECTIFIER POTASSIUM CHANNELS
    Arthur Brown; Fiscal Year: 2000
    ..Functional tests using patch clamp are performed simultaneously. For the second part of Aim 5, a variety of candidate modifier subunits that we have cloned will be tested for their ability to make hIRK more closely mimic I-Kr. ..
  35. ELECTROPHYSIOLOGY OF CARDIAC ARRHYTHMIAS
    Charles Antzelevitch; Fiscal Year: 1991
    ..The ultimate goal of the study is to provide information that will lead to a more definitive and less empiric approach in the pharmacologic and medical management of cardiac rhythm disturbances...
  36. MECHANISMS OF ANTIARRHYTHMIC ACTION IN REETRANT RHYTHMS
    LAWRENCE FRAME; Fiscal Year: 1999
    ..Histological studies will be performed to analyze the structural basis for critical sites if variable conduction and block and for bystander tissue that activates late or intermittently in the atrial tricuspid ring. ..
  37. CLINICAL TRIAL MANAGAEMENT OF FIBRILLATION
    H Greene; Fiscal Year: 2000
    ....
  38. MODELS OF ECTOPIC ATRIAL AUTOMATICITY
    GEORGE ROZANSKI; Fiscal Year: 1991
    ..This information may be of use in identifying effective pharmacologic approaches for the management of intermittent or sustained atrial tachyarrhythmias...
  39. STUDIES OF SURVIVORS OF PREHOSPITAL CARDIAC ARREST
    Robert Myerburg; Fiscal Year: 1980
    ..Similar short-term (8 hours) studies are being carried out to determine the relationship between diurnal variations in frequency of arrhythmias and corresponding fluctuations in blood levels of antiarrhythmic agents...
  40. ANTIARRHYTHMIC MECHANISMS IN ISCHEMIC MYOCARDIUM
    JODIE HURWITZ; Fiscal Year: 1990
    ..The contribution of the possible effects of changes in these ionic species in cardiac myocytes with and without application of antiarrhythmic drugs can be directly assessed...
  41. STRUCTURAL DETERMINANTS OF POTASSIUM CHANNEL FUNCTION
    Michael Lauer; Fiscal Year: 1992
    ..Site-specific mutagenesis of K+ channel cDNAs in conjunction with mRNA expression in Xenopus oocytes and patch clamping allows one to study these structure-function relationships...
  42. ELECTRICAL REMODELING, REPOLARIZATION & ANTIARRHYTHMICS
    Michael Rosen; Fiscal Year: 2000
    ..The applicant anticipates that the results will enhance our understanding of the plasticity of and control of the events that determine cardiac repolarization, and with this, identify new strategies for arrhythmia prevention. ..
  43. Automated Storage and Retrieval of Biological Systems
    Dan Roden; Fiscal Year: 2008
    ..Accordingly, this proposal requests a high end instrument to accomplish these goals, and to thereby enable a new era of Personalized Medicine. [unreadable] [unreadable] [unreadable] [unreadable]..
  44. Molecular Pathology of Cardic Arrhythmias
    Dan Roden; Fiscal Year: 2003
    ..abstract_text> ..
  45. HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
    Dan Roden; Fiscal Year: 2006
    ..Moreover, variability in the extent of rifampin-mediated induction of the drug metabolizing enzyme, CYP3A, among subjects with variant OATP-C alleles, will also be tested. [unreadable] [unreadable]..
  46. Digoxin Chiral Isolates as Improved Pharmaceuticals
    John Somberg; Fiscal Year: 2005
    ..The advantage would be a treatment for AF that did not cause cardiac augmentation and vasoconstriction or a treatment for CHF that does not cause heart rate slowing or conduction disturbances. ..
  47. Dietary Omega-3 Fatty Acids and Sudden Cardiac Death
    GEORGE EDWARD BILLMAN; Fiscal Year: 2010
    ..This project will also determine the effectiveness of fish oil supplements in reducing sudden death due to a lethal abnormal heart rhythm after a heart attack. ..
  48. Effect of Daily Exercise on Cardiac Autonomic Regulation
    GEORGE BILLMAN; Fiscal Year: 2005
    ..Ventricular contractile responses to Beta1- and Beta2-adrenoceptor stimulation will be examined in vivo by echocardiography and in vitro by single cell fluorescence microscopy/video edge detection. ..
  49. MOLECULAR BASIS OF LIGAND/SODIUM CHANNEL INTERACTIONS
    GING WANG; Fiscal Year: 2002
    ....
  50. Tau Nitration in Alzheimer's Pathogenesis
    Matthew Reynolds; Fiscal Year: 2007
    ..In this proposal, we will characterize the specific sites of T nitration in vitro and in situ, and determine the effects of nitration on T folding and function. ..
  51. THERAPEUTIC NA+ CHANNEL BLOCKERS: RECEPTOR & DRUG DESIGN
    GING WANG; Fiscal Year: 2007
    ..Such drugs, either taken orally or injected locally, may be beneficial for patients with chronic and intractable cancer pain. ..
  52. Cost Effectiveness of Catheter Ablation for Atrial Fibrillation (AF)
    Matthew Reynolds; Fiscal Year: 2008
    ..Once all of this data is collected, the necessary inputs will combined in a Markov model comparing AF ablation with antiarrhythmic drug therapy, and atrio-ventricular junctional ablation with pacemaker implantation. ..
  53. Mitochondria and Cardiac Cell Death
    James Weiss; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  54. Metabolic Oscillations in Heart
    JAMES N contact WEISS; Fiscal Year: 2010
    ..These insights may suggest novel therapies to protect the heart from injury during metabolic stresses such as heart attacks. ..